Actavis agrees to acquire Durata Therapeutics
October 06, 2014 at 08:44 AM EDT
Deal valued at about 4675 million is expected to strengthen Actavis’ infectious diseases business.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.